Plasmonic nanomaterials are poised to impact the clinical management of cancer through their ability to convert externally applied energy into localized heat at sites of diseased tissue. However, characterization of plasmonic nanomaterials as cancer therapeutics has been limited to xenograft models, creating a need to extend these¯ndings to more clinically relevant models of cancer. Here, we evaluate the method of photothermal ablation therapy in a genetically engineered mouse model (GEMM) of sarcoma, which more accurately recapitulates the human disease in terms of structure and biology than subcutaneous xenograft models. Using polyethylene glycol (PEG)-coated gold nanorods (PEG-NRs), we quantitatively evaluate the ability of nanoparticles to penetrate and accumulate in sarcomas through passive targeting mechanisms. We demonstrate that PEG-NRÀmediated photothermal heating results in signi¯cant delays in tumor growth with no progression in some instances. Lastly, by evaluating our photothermal ablation protocol in a GEMM, we observe o®-target heating e®ects that are not detectable in xenograft models and which may be of future clinical interest.
Introduction
In the last decade, nanoparticles and nanomaterials have been engineered for a wide array of biomedical applications. The clinical management of cancer stands to bene¯t greatly from nanoparticles that can more directly and selectively target tumors for diagnosis, imaging, and therapy. Noble metal nanomaterials are especially promising diagnostic, imaging, and therapeutic tools because they exhibit strong optical absorption and scattering properties due to an e®ect known as surface plasmon resonance. Gold nanoparticles are plasmonic materials which are characterized by facile synthesis and bioconjugation and low cytotoxicity 1À8 and which have demonstrated potential as multimodal diagnostic and therapeutic agents in vivo. 7, 9, 10 As diagnostic agents, gold nanoparticles enable imaging by optical coherence tomography (OCT), photoacoustic tomography, two-photon luminescence, X-ray computed tomography (CT), and surfaceenhanced Raman spectroscopy. 4 ,11À14 Therapeutically, strategies employing gold nanoparticles have harnessed their ability to selectively heat tumor tissue through the localized conversion of light into thermal energy. By varying their geometrical properties, gold nanoparticles, including nanoshells and nanorods, can be tuned to absorb speci¯c nearinfrared (NIR) wavelengths, at which biological tissue exhibits relatively low extinction coe±cients. Gold nanoparticleÀmediated photothermal ablation has shown considerable e±cacy in the treatment of cancer, leading to complete resolution of irradiated tumor xenografts in some cases. 6À8 Gold nanoparticleinduced heating has also been combined with other therapeutic modalities to leverage synergies between heat and radiation or chemotherapy, thereby sensitizing tumors to treatment. 15, 16 Finally, nanoparticle-induced heating has been used as a photothermal trigger in heat-responsive drug delivery systems. 17, 18 Despite the therapeutic promise of gold nanoparticles, translation to the clinic requires that their e®ectiveness be validated in physiologically relevant models of human cancer. To date, delivery of gold nanoparticles has been studied in subcutaneous xenograft tumors, and the accumulation of nanoparticles within xenografts has largely relied on passive targeting mechanisms. However, because subcutaneous xenografts fail to recapitulate important structural features of more clinically representative genetically engineered mouse models (GEMMs), the degree to which passive accumulation plays a role in tumor targeting within genetic models remains to be determined. 19À21 In particular, there is increasing evidence that tumor interstitial°uid pressure is model dependent and site speci¯c; therefore, pressure variations between subcutaneous xenografts, orthotopic models, and GEMMs may directly in°uence the extravasation across the vessel wall, the physical and biological entrapment of nanoparticles in the interstitium, and the intratumoral distribution of gold nanoparticles. 22 Di®erences in the anatomical location and geometry of the tumor in di®erent mouse models may further a®ect the ability to focus NIR light, induce speci¯c versus o®-target heating, and lethally ablate the tumor. Demonstrating the penetration and accumulation of gold nanoparticles, as well as their ability to induce site-speci¯c photothermal ablation in GEMMs, is therefore an important step as these particles are evaluated for their utility in the clinic.
Here, we sought to directly compare the e®ec-tiveness of a polyethylene (PEG)-coated nanorods (PEG-NR) ablative therapeutic protocol in a genetically engineered mouse model to previous results obtained in subcutaneous xenografts. 6À8 To assess the impact of PEG-NR ablative therapy, we selected a model of sarcoma harboring conditional mutations in Kras and Trp53 and resembling human sarcoma both in microscopic structure and by immunohistochemistry. 23 Our lab has previously developed polyethylene glycol (PEG)-coated gold nanorods which exhibit high stability in circulation (t 1=2 $ 17 h) and a high optical absorption coe±-cient. 7 Leveraging this technology, we show that intravenously injected PEG-NRs passively accumulate in both subcutaneous xenografts and the sarcoma GEMM. Additionally, NIR laser irradiation results in rapid, sarcoma-speci¯c heating and ablation, leading to signi¯cant delays in tumor growth. We further show loss of extremity function due to non-speci¯c heating of the sarcoma, an e®ect only observed in the GEMM. Collectively, these studies demonstrate that passively targeted PEG-NRs are capable of serving as highly absorbing antennas in a clinically relevant model of cancer, and suggest that an optimal combination of PEG-NR delivery and appropriate ablation protocol could be translated to clinical utility.
Materials and Methods

Preparation of PEG-coated gold NRs
Gold nanorods were prepared as described previously. 7 Brie°y, $ 10 Â 40 nm cetyltrimethylammonium bromide (CTAB)-coated gold NRs with longitudinal plasmon resonance at 810 (Nanopartz Inc.) were centrifuged at 16,000 rcf to concentrate and resuspended in 100 M of 5-kDa methyl-PEG-thiol (Layson Bio, Inc.). The solution of 5-kDa methyl-PEG-thiol and CTAB-coated gold NRs was mixed and dialyzed overnight against ultrapure water (18 M cm À1 ) using cellulose ester membrane dialysis (Spectrapor). Dialyzed samples were washed and¯ltered through 100-kDa¯lters (Millipore) to remove excess polymer, resuspended in PBS, and stored at 4 C.
Generation of soft tissue sarcomas
The mouse model of sarcoma was described previously by Kirsch et al. 23 The 129 S 4 /SvJae mouse strain was bred and used for the generation of transgenic sarcoma mice. These mice harbor the following conditional mutations: LSL-Kras G12D=þ and p53 Fl=Fl . Soft tissue sarcomas were generated by intramuscular injection of 2:4 Â 10 7 pfu of adenovirus (Ad-Cre) expressing Cre-recombinase (Gene Vector Transfer Core, University of Iowa) in the lower extremity. All animal studies and procedures were approved by the MIT and MGH Institutional Animal Care and Use Committees.
Generation of HT-1080 xenografts
To generate subcutaneous xenograft models, nude mice (Jackson Labs) were injected bilaterally in the hind°anks with $ 5 Â 10 6 HT-1080 cells suspended in 200 L DMEM.
Silver enhancement staining
Para±n-embedded tissue sections were dewaxed and rinsed with double-distilled water for up to 30 sec. Silver enhancement was performed using the Silver Enhancer Kit for Membranes (Cytodiagnostics). Equal volumes of Silver Enhancer Solution A and Silver Enhancer Solution B were mixed, and 50À100 L was added to tissue sections, ensuring that the entire tissue was covered. Several dilutions of Solution A/Solution B mixtures in double-distilled water were tested. To determine the optimal enhancement time, representative 20X¯elds were imaged every 10 min for up to 80 min (Nikon ECLIPSE Ti). After incubation in silver enhancement solution, tissues were rinsed well with doubledistilled water for up to 60 sec. Samples were counterstained with hematoxylin, dehydrated, and mounted using standard protocols.
Quanti¯cation of silver deposits was performed using ImageJ software. To generate particle counts, the Analyze Particles command was applied to each contrast-enhanced, 8-bit, thresholded image. The same thresholding values were applied to all images included in the analysis.
ICP-MS
Samples for inductively coupled plasma mass spectrometry, or ICP-MS analysis, were frozen, lyophilized, and dissolved in aqua regia, prepared by adding 100 L of HNO 3 to 300 L of 37% HCl for 72 h to dissolve gold particles. Then, samples were diluted to 10 mL with 9.6 mL of 2% HNO 3 and analyzed via ICP-MS against standards (ThermoScienti¯c Finnigan ELEMENT2). Control saline and organ samples with exogenously added GNRs were used for calibration.
In vivo photothermal therapy
Approximately 90 days after injection of Ad-Cre, mice bearing sarcomas between 150À200 mm 3 were randomized into one of three groups: PEG-NR þ NIR, PEG-NR only, and NIR only (n ¼ 4À5 mice per group). Mice were then injected through the tail vein with PEG-NRs in PBS (40 mg Au/kg). After allowing 72 h for vascular clearance of PEGNRs, the mice were anaesthetized with ketamine/ xylazine and sarcomas were irradiated with a NIR laser ($0.5 W/cm 2 , 810 nm, $1-cm beam diameter). Prior to irradiation, the area around the tumor was shaved to remove excess hair. To monitor surface temperature during irradiation, an infrared thermographic camera (FLIR, Thermacam S60) was used. To assess tumor growth following treatment, tumors were measured every two to three days using digital calipers. Mice were euthanized when tumors exceeded 15 mm in any single dimension.
Immunohistochemistry
Immunohistochemistry was performed as described previously. 24 Brie°y, immunostaining was performed on formalin-¯xed para±n embedded sections following antigen retrieval (10 mM citrate bu®er (pH $ 6:0) at 95 C for 20 min; 22 C for 20 min). Primary antibodies rat anti-mouse CD31 (1:100, Pharmingen, San Jose, CA, USA) and mouse anti-PCNA (1:500, PC-10; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were applied to tissue sections for 1 h at room temperature. Secondary antibodies were applied for 30 min at room temperature: biotinylated rabbit anti-rat IgG (1:1000, Vector Laboratories, Burlingame, CA, USA) or biotinylated horse anti-mouse IgG (1:1000, Vector Laboratories, Burlingame, CA, USA). Sections were then incubated for 30 min with ABC reagent (Vector Laboratories, Burlingame, CA, USA), rinsed with PBS-T, and incubated in DAB chromagen reagent (Vector Laboratories, Burlingame, CA, USA). The sections were rinsed under running tap water for 5 min and counterstained in Mayer's Hematoxylin (Sigma, St. Louis, MO USA), dehydrated, and mounted using Permount (Fisher Scienti¯c, Pittsburgh, PA, USA). Standard hematoxylin and eosin (H&E) staining was performed on tissue sections.
Results
Sarcoma treatment and experimental schedule
Sarcoma-bearing mice were injected with either PEG-NRs or PBS control and subjected to the photothermal ablation protocol [ Fig. 1(a) ]. Following irradiation, mice in the treatment trial were regularly monitored for tumor burden. A second group of mice was sacri¯ced either 24 or 72 h after ablation to assess the short-term histopathological e®ects of ablation. We veri¯ed the uniform structure of PEG-NRs by transmission electron microscopy [ Fig. 1(b) ] and demonstrated the capacity of PEG-NRs to speci¯-cally and signi¯cantly heat sarcomas exposed to NIR irradiation 
Comparison of PEG-NR accumulation in GEMM and xenograft models of sarcoma
To con¯rm the presence of PEG-NR accumulation in the tumor interstitium of both the GEMM and Fig. 2(e) ]. Additionally, we did not detect signi¯cant silver deposits in surrounding tissues, including skeletal muscle, indicating that PEG-NRs accumulated preferentially in sarcomas (Supp. Fig. 2 ). ICP-MS con¯rmed the presence of gold in the GEMMs (6.60 %ID/g) in amounts comparable to those seen in the HT-1080 xenografts (11.32 %ID/g) [ Fig. 2(f) ]. These results directly con¯rm that PEG-NRs are able to penetrate and accumulate in sarcoma GEMMs in amounts su±-cient for photothermal ablation protocols.
Immunohistochemistry of tumors following photothermal ablation
Examination of H&E-stained para±n sections revealed regions of gross necrosis at 24 and 72 h post-irradiation. These sections were characterized by loss of tumor architecture, cellularly hypodense regions, lymphocytic in¯ltrates, and irregular nuclear staining patterns (Fig. 3 and Supp. Fig. 3 ). These regions likely correspond to the portions of the tumor receiving the majority of photothermal energy during the ablation procedure.
To assess cellular proliferation, we immunohistochemically stained the sarcoma sections for proliferating cell nuclear antigen (PCNA). Consistent with the H&E results, we observed wide regions of absent PCNA staining throughout the tumors at 24 and 72 h following ablation (Fig. 3) . Interestingly, we identi¯ed isolated regions located exclusively at sites of the tumor most distal from the skin surface that stained positively for PCNA. These areas of viable tissue account for anywhere between 0% to approximately 20% of the area of some tissue sections (Supp. Fig. 3 ), suggesting that some portions of the tumor did not receive su±cient photothermal energy during the ablation procedure. Finally, to understand how photothermal ablation in°uences the distribution of blood vessels in the sarcoma, we measured expression of CD31, an endothelial cell marker commonly used to identify blood vessels. Necrotic regions exhibited di®use, non-speci¯c staining patterns bearing no resemblance to the blood vessels observed in untreated control tissue (Supp. Fig. 4) . Thus, in regions of tumor receiving su±cient irradiative heat to induce necrosis, the tumor-associated vasculature is also ablated.
Therapeutic assessment of photothermal ablation in a transgenic sarcoma model
To test the ability of a single dose of PEG-NRs to signi¯cantly delay tumor growth following one session of near-IR irradiation, genetically modi¯ed 129 S 4 /SvJae mice-bearing-induced soft tissue sarcomas were injected with PEG-NRs. Mice were randomized to one of three cohorts (PEG-NRs þ NIR, PEG-NRs only, NIR only). After plasma clearance of PEG-NRs, tumors in the PEG-NRs þ NIR and NIR only groups were irradiated for 5 min ($0.5 W/cm 2 , 810 nm) and tumor volume was measured over time [ Fig. 4(a) ]. Mice receiving the PEG-NRs þ NIR treatment experienced signi¯cant tumor growth delay and extended lifespan compared to control treatment groups. During the post-ablation observation period, all mice in the PEG-NRÀonly and NIR only groups developed substantial tumor burdens requiring euthanization by day 16, whereas mice receiving PEG-NRs þ NIR survived until day 30 or longer [ Fig. 4(b) ]. At the end of the study period, the two remaining mice had tumor volumes < 150 mm 3 (Supp. Fig. 5 ). Notably, four of the¯ve mice receiving PEG-NR þ NIR lost lower extremity function after the ablation procedure. Additionally, in a repeat therapeutic trial, we observed delayed progression of sarcoma consistent with our initial results.
Discussion
Surgery, chemotherapy, and radiation have remained the standard of care in cancer therapy for decades. Novel approaches harnessing the unique properties of nanomaterials have been proposed to improve cancer therapy in the future. To date, numerous therapeutic protocols, involving a variety of nanomaterials, have been described in xenograft mouse models. While xenograft models o®er a straightforward and reliable method for quantitatively assessing tumor burden, studies in more physiologic tumor microenvironments, such as those that occur in GEMMs, may be more accurate predictors of therapeutic e±cacy. 25 For these reasons, GEMMs are gaining favor in the pharmaceutical industry and will almost certainly¯nd utility in assessing the clinical validity of nanomaterial-based therapeutic protocols as well.
This study represents the¯rst demonstration of a therapeutic, nanoparticle-mediated thermal ablation protocol in a GEMM. We have demonstrated that PEG-NRs accumulate in the sarcomas at levels comparable to those in subcutaneous HT-1080 xenografts. Deposition of PEG-NRs is su±cient to facilitate photothermal ablation of the sarcomas upon localized administration of near-infrared irradiation.
Although numerous lines of evidence support the notion that passively targeted nanotherapeutics can penetrate and accumulate in human tumors, this phenomenon has not been well characterized in a clinical setting. 26, 27 Routinely used xenograft models fail to capture important characteristics of human disease that may impact the e®ectiveness of passive targeting mechanisms. 19 This uncertainty is signi¯-cant as many nanotherapeutic approaches rely on passive targeting to varying degrees in order for the therapeutic payload to accumulate at the site of disease. Our demonstration of untargeted PEG-NR accumulation in a GEMM of sarcoma provides evidence that passive targeting is indeed su±cient for PEG-NRs to accumulate in a physiologic tumor microenvironment.
The considerable heterogeneity of human cancers is an important factor for PEG-NR-based therapies. It is not anticipated that a \one-size-¯ts-all" therapy will be identi¯ed, but rather that therapeutic protocols must be tailored to each type of cancer. Features including grade, stage, tissue of origin, anatomical location, and metastatic progression will in°uence if, and to what extent, PEG-NR-based therapies will have a place in the clinic. 23, 28, 29 For example, because of constraints related to depth of NIR irradiation into tissues, tumors that develop close to the skin surface, such as some soft tissue sarcomas, would be better candidates for PEG-NR-based therapies than tumors that develop at sites more distant from the skin surface. Interestingly, in our GEMM, a portion of the sarcoma developed closer to the surface while the remainder developed deeper within surrounding skeletal muscle. In contrast to HT-1080 xenograft models which replicate super¯cial truncal tumors, our GEMM replicates a deep extremity sarcoma, which represents the majority of human sarcomas. We propose that this spatial heterogeneity contributed to the di®erential success in ablative therapy that we observed. Additionally, tumors that are identi¯ed at earlier stages may be better candidates for PEG-NR therapies than tumors identi¯ed at late stages, such as pancreatic adenocarcinoma, 30 because of the increased challenge of optimally irradiating multiple metastatic lesions. Notably, a signi¯cant proportion of mice to undergo photothermal ablation lost function in the irradiated limb following treatment. Because the sarcomas invade surrounding skeletal muscle, the thermal energy generated within the sarcoma damaged the skeletal muscle as well as the sciatic and femoral nerves in the leg. We believe this observation is important in two respects. First, it suggests that improvements are required in the irradiation protocol to provide more precise thermal ablation at cellular resolution. Pulsed laser sources represent one possibility for improving the localization of photothermal ablation. Second, this unwanted side e®ect of the therapy could only be detected and fully appreciated in a GEMM, in which the sarcoma's anatomical location closely mimics that of human extremity soft tissue sarcomas. While a subcutaneous xenograft model can provide important information such as tumor burden in response to treatment, only in a GEMM can these realistic clinical consequences be detected and assessed.
Conclusion
The ability of mouse models to accurately recapitulate human cancers and yield clinically insightful results is critical to the continuing development of nanotechnology for therapy and diagnostics. Our work highlights the therapeutic e±cacy and potential challenges of PEG-NRÀmediated photothermal ablation therapy in a GEMM of sarcoma. We anticipate that our¯ndings will enable the development of improved therapeutic protocols as PEG-NRs and other nanotherapeutics advance closer to clinical use. Gold Nanorod Photothermal Therapy in a Genetically Engineered Mouse Model 287
